Warning: Declaration of AMW_Related_Sub_Items_Walker::walk($elements, $max_depth) should be compatible with Walker::walk($elements, $max_depth, ...$args) in /home/cnmhopkins/www/www/wp-content/plugins/advanced-menu-widget/class-advanced-menu-walker.php on line 163
Nanomedicine for Cancer : Center for Nanomedicine

Nanomedicine for Cancer

cardiovascularCancers are as diverse as they are devastating. Drugs that kill tumor cells, known as chemotherapy, are administered systemically (through the blood). The major limitation to this approach is that chemotherapy drugs not only kill tumor cells, but kill other dividing cells, including hair follicles and cells of the immune system and digestive tract. The small fraction of drug that actually reaches the tumor then does not penetrate into the tumor to reach all of the tumor cells. To improve the effectiveness of cancer therapies, nanotechnologies can be used to focus delivery to the tumor tissues, deliver smaller therapeutic doses in a sustained manner over time, and improve drug penetration into the tumor tissue. Our nanoparticles are engineered with surface coatings that overcome mucosal barriers on epithelial tumors, as well as allow penetration through tissue to allow for drug to reach more of the tumor cells (see Technologies).

Additionally, cancers cells have the ability to evade the body’s biochemical signal for programmed cell death, called apoptosis. Resistance to apoptosis in tumor cells can be overcome with chemotherapeutics, as well as proteins that bind to specific receptors found on the surface of cancer cells. We are developing engineered TNF-related apoptosis-inducing ligand (TRAIL) agonists as universal cancer-targeted therapies to induce cancer cell death. Such nanomedicines can provide more effective eradication of tumors.

Disease Focus Areas

  • Cervical cancer
  • Ovarian cancer
  • Lung cancer
  • Brain cancer
  • Colorectal cancer

Selected publications

Nance E, Zhang C, Shih T-Y, Xu Q, Schuster BS, Hanes J. (2014) Brain-penetrating nanoparticles improve paclitaxel efficacy in malignant glioma following local administration, ACS Nano, 8(10): 10655-64.

Tang BC, Fu J, Watkins DN, Hanes J. (2010) Enhanced efficacy of local etoposide delivery by poly(ether-anhydride) particles against small cell lung cancer in vivo, Biomaterials, 31: 339-344.

Kim TH, Swierczewska M, Kim A, Jo DG, Park JH, Byuan Y, Sadegh-Nasseri S, Pomper MG, Lee KC, Lee S. (2013) Mix to validate: a facile, reversible PEGylation for fast screening of potential therapeutic proteins in vivo, Angew Chem Int Ed Engl, 52(27): 6880-4.

Yang M, Yu T, Wang YY, Lai SK, Zeng Qi, Miao B, Tang BC, Simons B, Ensign L, Liu G, Chan K, Juang C, Mert O, Wood J, Fu J, McMahon M, Wu TC, Hung CF, Hanes J. (2013) Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth, Adv Healthc Mat, 3(7):1044-52.